Bayer, Curadev Enter ‘STING’ Pact Exploring Inflammatory Disease
Duo Using Curadev’s Stimulator Of Interferon Genes Antagonist Platform
Executive Summary
Bayer and Curadev entered a research collaboration and license agreement to develop novel STING antagonists targeting inflammatory disease.
You may also be interested in...
Bayer Back In M&A Mode To Boost Pipeline
The head of the German group's pharma BD team tells Scrip that Bayer has created a system which allows it to move quickly when sealing partnerships, as seen with the KaNDy buy on 11 August.
Deal Watch: Coronavirus Collaborations Reflect Industry’s Full Press Pandemic Response
Deals involving Hoth/Voltron, Vir/Xencor, Akers/Premas, WPD/CNS address coronavirus outbreak. Separately, Roche and Forge hope to develop a novel antibiotic for Gram-negative infections using the LpxC enzyme.
Asia Deal Watch: Takeda Licenses Curadev STING Agonist To Further Its IO Ambitions
The Japanese pharma, continuing to bolster its pipeline after buying Shire, is partnering with Skyhawk in neurodegenerative diseases under another new deal. Also, Purdue cites shifting business priorities for a decision to end Eisai collaboration on sleep disorder drug.